Decitabine in TP53-Mutated AML.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. Eprenetapopt Plus Azacitidine inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
   Trial
2. Allogeneic transplantation in adverse-risk acute myeloid leukemia: Challenges, strategies, and future directions.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025
   Article
3. Hypermethylation of microRNA-34c CpG Island predicts unfavorable prognosis in acute myeloid leukemia.Scientific reports · 2025
   Article
4. An enteropathogenic microbial toxin modulates the breast cancer epigenome resulting in concurrent silencing of tumor suppressor genes.Breast cancer research : BCR · 2025
   Article
5. Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation block.Blood cancer journal · 2025
   Article
6. Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.Blood advances · 2023
   Article
7. Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy.Molecular cancer · 2023
   Article
8. Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives.Blood reviews · 2023
   Review
9. How I TreatCancers · 2022
   Review
10. The genetics of myelodysplastic syndromes and the opportunities for tailored treatments.Frontiers in oncology · 2022
    Review
11. A precision medicine approach to management of acute myeloid leukemia in older adults.Current opinion in oncology · 2020
    Review
12. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML.Blood advances · 2020
    Article
13. Hypomethylating Agent Azacitidine Is Effective in Treating Brain Metastasis Triple-Negative Breast Cancer Through Regulation of DNA Methylation of Keratin 18 Gene.Translational oncology · 2020
    Article
14. Genetic abnormalities and pathophysiology of MDS.International journal of clinical oncology · 2019
    Review
15. The Progress of Next Generation Sequencing in the Assessment of Myeloid MalignanciesBalkan medical journal · 2019
    Article
16. Management of myelodysplastic syndromes after failure of response to hypomethylating agents.Therapeutic advances in hematology · 2019
    Review
17. Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report.Frontiers of medicine · 2018
    Article
18. Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.Oncotarget · 2018
    Review
19. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.Blood · 2017
    Review

Corrections and comments

• Comment on
  Decitabine in TP53-Mutated AML.2017

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as